EMUC 2017: Partial Metastasectomy and Targeted Therapy for Renal Cell Carcinoma
Incomplete resection of renal cell carcinoma metastases may be associated with increased efficacy of first-line targeted therapy and improved long-term survival in patients with metastatic renal cell carcinoma, according to research presented by Pavel Borisov, MD, of St. Petersburg Clinical Oncological Dispensary, Department of Urology, Saint-Petersburg, Russia, and colleagues, at the 2017 European Multidisciplinary Meeting on Urological Cancers (EMUC) in Barcelona (Abstract P101). Further trials are necessary, however, to establish the role of incomplete metastasectomy in this patient population, they added.
Complete metastasectomy in patients with surgically resectable metastases plays an important role in the management of metastatic renal cell carcinoma. In this retrospective study, however, the investigators sought to evaluate the efficacy of partial metastasectomy and subsequent targeted therapy (including sunitinib, bevacizumab plus interferon, pazopanib, sorafenib, axitinib, everolimus, and immunotherapy).
Data were collected on 147 patients with clear cell renal cell carcinoma and metastases at presentation who underwent partial metastasectomy followed by systemic therapy (n=47) or systemic therapy alone (n=100). These patients were treated from 2008 to 2015. The median follow-up was 31.2 months.
The investigators revealed that partial metastasectomy significantly increased progression-free survival in first-line therapy. Additionally, there appeared to be a trend toward a survival benefit in patients who underwent partial metastasectomy and systemic treatment, with a median overall survival of 46 months, compared with 31 months in patients treated with systemic therapy alone.